跳至主要内容
临床试验/CTRI/2023/04/052140
CTRI/2023/04/052140尚未招募Unknown

Ondansetron as an adjunctive therapy in positive, negative and cognitive symptoms of schizophrenia: A randomized double-blind placebo controlled study

Central Institute of Psychiatry0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Inpatients satisfying the ICD 10-DCR [1993] criteria for schizophrenia
  • 2.Current positive symptoms rated >=4 (moderate) on one or more of these BPRS items: conceptual disorganization, grandiosity, hallucinatory behaviour and unusual thought content.
  • 3.Age 18 - 60 years of both sexes.
  • 4.Illness duration of equal to or more than 2 years.
  • 5.Those who give informed consent for participating in the study

排除标准

  • 1.Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine.
  • 2.Known hypersensitivity to Tab. Ondansetron or any of its components.
  • 3.Receiving concomitant Apomorphine.
  • 4.Deranged liver function test (Alanine transaminase >= 180 IU/l and/or Aspartate transaminase >= 140 IU/l).
  • 5.Significant current/past medical or neurological illness including severe hepatic disease and history of severe head injury.
  • 6.Patients who received ECT in the last 6 months or currently receiving ECT.
  • 7.QTc interval >= 450ms in males and >= 470ms in females on Electrocardiogram (ECG).
  • 8.Pregnancy.

研究者

相似试验